Live Breaking News & Updates on Promethos Capital

StockNews.com cut shares of Dr. Reddy’s Laboratories (NYSE:RDY – Free Report) from a strong-buy rating to a buy rating in a research report report published on Thursday morning. Separately, Barclays lifted their price target on shares of Dr. Reddy’s Laboratories from $80.00 to $81.00 and gave the company an overweight rating in a research note […] ....

Healthcare Of Ontario Pension Plan Trust Fund , Mission Capital , Reddy Laboratories , Bessemer Group Inc , Reddy Laboratories Company Profile , Promethos Capital , Free Report , Street Group , Ontario Pension Plan Trust Fund , Get Free Report , Laboratories Limited , Global Generics , Pharmaceutical Services , Active Ingredients , Laboratories Daily ,